清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial

医学 养生 不利影响 内科学 随机对照试验 幽门螺杆菌 置信区间 入射(几何) 抗生素 塔特布 临床试验 前瞻性队列研究 药物治疗 抗菌剂 意向治疗分析
作者
Yucheng Zhu,Keng Li,Anjiang Sun,Sihui Lin,J I A N Zhang,ShanShan Meng,Xin Xia,H X Gao,Juan Lin,Wei Jiang
出处
期刊:Helicobacter [Wiley]
卷期号:31 (3): e70147-e70147
标识
DOI:10.1111/hel.70147
摘要

BACKGROUND: Resistance to antibiotics has resulted in the effectiveness of conventional eradication therapies for Helicobacter pylori being reduced, creating a need for regimens that are effective, safe, and simple. In this study, we evaluated the eradication efficacy, adverse events, and medication adherence of four different tegoprazan-based regimens administered as first-line therapy for H. pylori infection. We also explored the clinical value of adding bismuth to a triple therapy regimen. METHODS: In this prospective, randomized controlled trial, 640 treatment-naive patients with confirmed H. pylori infection were randomly assigned to one of the four groups undergoing 14-day treatment regimens of tegoprazan-amoxicillin (TA), tegoprazan-tetracycline (TT), tegoprazan-amoxicillin-tetracycline (TAT), or tegoprazan-amoxicillin-tetracycline-bismuth (TATB), with 160 patients in each group. The outcomes were the eradication rate, incidence of adverse events, and medication adherence. RESULTS: In the intention-to-treat analysis, the H. pylori eradication rates in the TA, TT, TAT, and TATB groups were 80.0% (95% confidence interval [CI]: 73.0-85.9), 61.9% (95% CI: 53.9-69.4), 93.1% (95% CI: 88.0-96.5), and 89.4% (95% CI: 83.5-93.7), respectively. Compared with the TATB regimen, the TAT regimen was non-inferior (95% CI, -3.9% to 11.5%; non-inferiority p < 0.001), whereas demonstrating non-inferiority in the TA and TT regimens failed. Adverse events were less frequent in the TA (10.6%), TT (17.5%), and TAT (20.0%) groups than in the TATB group (36.9%; all p < 0.001). Medication adherence was high across groups, with no significant between-group differences observed. CONCLUSIONS: High eradication efficacy was demonstrated for the TAT regimen; this regimen was non-inferior to the TATB regimen, and it was associated with fewer adverse events. These findings suggest that it may be an effective first-line treatment option for H. pylori infection. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06977841.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
8秒前
8秒前
科研通AI6.4的应助被纯情的阁采纳,获得10
9秒前
科研通AI6.4的应助被纯情的阁采纳,获得30
9秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
9秒前
池雨完成签到 ,获得积分10
24秒前
苗条的香萱完成签到,获得积分10
32秒前
年轻狗完成签到,获得积分10
37秒前
39秒前
44秒前
研友_nqrKQZ发布了新的文献求助10
44秒前
隐形曼青的应助被研友_nqrKQZ采纳,获得10
51秒前
52秒前
爱听歌的语堂完成签到,获得积分10
53秒前
55秒前
1分钟前
1分钟前
1分钟前
纯情的阁发布了新的文献求助10
1分钟前
搞怪山河完成签到,获得积分10
1分钟前
1分钟前
纯情的阁发布了新的文献求助10
1分钟前
星辰大海的应助被天熙采纳,获得10
1分钟前
纯情的阁发布了新的文献求助30
1分钟前
1分钟前
纯情的阁发布了新的文献求助10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得30
1分钟前
1分钟前
1分钟前
xun发布了新的文献求助10
1分钟前
1分钟前
天熙发布了新的文献求助10
1分钟前
1分钟前
如意涵雁完成签到,获得积分10
1分钟前
傲娇的秋天完成签到,获得积分10
1分钟前
1分钟前
积极的向彤完成签到,获得积分10
1分钟前
认真太阳完成签到,获得积分10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158905
求助须知:如何正确求助?哪些是违规求助? 9554522
关于积分的说明 21719373
捐赠科研通 7748459
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552006
邀请新用户注册赠送积分活动 2471370